Literature DB >> 10992461

Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.

B R Brodeur1, M Boyer, I Charlebois, J Hamel, F Couture, C R Rioux, D Martin.   

Abstract

A protein of group B streptococci (GBS), named Sip for surface immunogenic protein, which is distinct from previously described surface proteins, was identified after immunological screening of a genomic library. Immunoblots using a Sip-specific monoclonal antibody indicated that a protein band with an approximate molecular mass of 53 kDa which did not vary in size was present in every GBS strain tested. Representatives of all nine GBS serotypes were included in the panel of strains. Cloning and sequencing of the sip gene revealed an open reading frame of 1,305 nucleotides coding for a polypeptide of 434 amino acid residues, with a calculated pI of 6. 84 and molecular mass of 45.5 kDa. Comparison of the nucleotide sequences from six different strains confirmed with 98% identity that the sip gene is highly conserved among GBS isolates. N-terminal amino acid sequencing also indicated the presence of a 25-amino-acid signal peptide which is cleaved in the mature protein. More importantly, immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI. The data presented in this study suggest that this highly conserved protein induces cross-protective immunity against GBS infections and emphasize its potential as a universal vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992461      PMCID: PMC101513          DOI: 10.1128/IAI.68.10.5610-5618.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

Review 1.  The Tat protein export pathway.

Authors:  B C Berks; F Sargent; T Palmer
Journal:  Mol Microbiol       Date:  2000-01       Impact factor: 3.501

2.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Cloning and sequence analysis of zooA, a Streptococcus zooepidemicus gene encoding a bacteriocin-like inhibitory substance having a domain structure similar to that of lysostaphin.

Authors:  R S Simmonds; W J Simpson; J R Tagg
Journal:  Gene       Date:  1997-04-21       Impact factor: 3.688

4.  Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V.

Authors:  T Areschoug; M Stålhammar-Carlemalm; C Larsson; G Lindahl
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

5.  Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection.

Authors:  F Y Lin; J D Clemens; P H Azimi; J A Regan; L E Weisman; J B Philips; G G Rhoads; P Clark; R A Brenner; P Ferrieri
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

6.  Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program.

Authors:  L H Harrison; J A Elliott; D M Dwyer; J P Libonati; P Ferrieri; L Billmann; A Schuchat
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

7.  Surface protein expression in group B streptococcal invasive isolates.

Authors:  P Ferrieri; A E Flores
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

8.  Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women.

Authors:  C S Lachenauer; D L Kasper; J Shimada; Y Ichiman; H Ohtsuka; M Kaku; L C Paoletti; P Ferrieri; L C Madoff
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

Review 9.  Maternal immunization.

Authors:  W P Glezen; M Alpers
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

10.  Type-specific antigens of group B type Ic streptococci.

Authors:  H W Wilkinson; R G Eagon
Journal:  Infect Immun       Date:  1971-11       Impact factor: 3.441

View more
  54 in total

1.  Localization of surface immunogenic protein on group B streptococcus.

Authors:  S Rioux; D Martin; H W Ackermann; J Dumont; J Hamel; B R Brodeur
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.

Authors:  Francesco Doro; Sabrina Liberatori; Manuel J Rodríguez-Ortega; Cira D Rinaudo; Roberto Rosini; Marirosa Mora; Maria Scarselli; Emrah Altindis; Romina D'Aurizio; Maria Stella; Immaculada Margarit; Domenico Maione; John L Telford; Nathalie Norais; Guido Grandi
Journal:  Mol Cell Proteomics       Date:  2009-04-28       Impact factor: 5.911

4.  CsrRS regulates group B Streptococcus virulence gene expression in response to environmental pH: a new perspective on vaccine development.

Authors:  Isabella Santi; Renata Grifantini; Sheng-Mei Jiang; Cecilia Brettoni; Guido Grandi; Michael R Wessels; Marco Soriani
Journal:  J Bacteriol       Date:  2009-06-19       Impact factor: 3.490

5.  Putative novel surface-exposed Streptococcus agalactiae protein frequently expressed by the group B streptococcus from Zimbabwe.

Authors:  Rooyen T Mavenyengwa; Johan A Maeland; Sylvester R Moyo
Journal:  Clin Vaccine Immunol       Date:  2009-07-08

Review 6.  Streptococcus adherence and colonization.

Authors:  Angela H Nobbs; Richard J Lamont; Howard F Jenkinson
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

Review 7.  Vaccinology in the genome era.

Authors:  C Daniela Rinaudo; John L Telford; Rino Rappuoli; Kate L Seib
Journal:  J Clin Invest       Date:  2009-09       Impact factor: 14.808

8.  Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.

Authors:  Hsiao-Hui Yang; Lawrence C Madoff; Hilde-Kari Guttormsen; Yong-Dong Liu; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae.

Authors:  Herve Tettelin; Vega Masignani; Michael J Cieslewicz; Jonathan A Eisen; Scott Peterson; Michael R Wessels; Ian T Paulsen; Karen E Nelson; Immaculada Margarit; Timothy D Read; Lawrence C Madoff; Alex M Wolf; Maureen J Beanan; Lauren M Brinkac; Sean C Daugherty; Robert T DeBoy; A Scott Durkin; James F Kolonay; Ramana Madupu; Matthew R Lewis; Diana Radune; Nadezhda B Fedorova; David Scanlan; Hoda Khouri; Stephanie Mulligan; Heather A Carty; Robin T Cline; Susan E Van Aken; John Gill; Maria Scarselli; Marirosa Mora; Emilia T Iacobini; Cecilia Brettoni; Giuliano Galli; Massimo Mariani; Filippo Vegni; Domenico Maione; Daniela Rinaudo; Rino Rappuoli; John L Telford; Dennis L Kasper; Guido Grandi; Claire M Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-28       Impact factor: 11.205

Review 10.  Group B Streptococcus vaccine: state of the art.

Authors:  Annalisa Nuccitelli; C Daniela Rinaudo; Domenico Maione
Journal:  Ther Adv Vaccines       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.